<DOC>
	<DOCNO>NCT02397460</DOCNO>
	<brief_summary>This double-blind , randomize , 4 period , crossover study 30 male female healthy chronic cough subject .</brief_summary>
	<brief_title>Effect AF-219 Cough Reflex Sensitivity</brief_title>
	<detailed_description>Up 30 subject meet entry criterion randomly assign AF-219 match placebo . There Screening Period , Baseline Visit ( cough subject ) , four Treatment Periods , washout period treatment . Subjects return last Treatment Visit Follow-up Visit . At Screening Visit Treatment Periods , cough sensitivity measure standard clinical methodology incorporate two cough challenge ( capsaicin ATP ) . The ATP challenge perform study treatment period . The Baseline Visit ( cough subject ) occur prior Treatment Period 1 . Day time cough monitoring perform Baseline Visit four Treatment Periods ( cough subject ) .</detailed_description>
	<mesh_term>Cough</mesh_term>
	<criteria>Have provide write informed voluntary consent ; Be able speak , read , understand English ; Be male female , race , 18 80 year age , inclusive ; Have body mass index ( BMI ) â‰¥18 &lt; 35.0 kg/m2 ; Be good general health clinically relevant abnormality base medical history , physical examination , clinical laboratory evaluation ( hematology , clinical chemistry , urinalysis ) , 12 lead electrocardiogram ; Women child bear potential must negative pregnancy test Screening prior randomization . Women childbearing potential must use 2 method acceptable birth control Screening 3 month last dose study drug ; Male subject partner childbearing potential ( define Inclusion No . 8 ) must use 2 method acceptable birth control , 1 must barrier method ; Subjects chronic cough Be able communicate effectively Investigator study center personnel agree comply study procedure restriction Current smoker ; Individuals give smoking within past 6 month , &gt; 20 packyear smoke history ( chronic cough subject ) , &gt; 10 packyear smoke history ( healthy subject ) ; History upper respiratory tract infection recent significant change pulmonary status within 4 week prior Screening prior randomization ; History concurrent malignancy recurrence malignancy within 2 year prior Screening ( exception &lt; 3 excised basal cell carcinoma ) ; History diagnosis drug alcohol dependency abuse within last 3 year ; In opinion Principal Investigator , uncontrolled unstable clinically significant neurological , psychiatric , respiratory , cardiovascular , peripheral vascular , gastrointestinal , hepatic , pancreatic , endocrinological , hematological , immunological disorder active infection ; Clinically significant abnormal electrocardiogram ( ECG ) Screening Significantly abnormal laboratory test Screening Breastfeeding ; In judgement Principal Investigator , severe , acute , chronic medical psychiatric condition laboratory abnormality may increase risk associate trial participation investigational product administration may interfere interpretation trial result would make subject inappropriate entry trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>